Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma Clinical Trial

Official title:

A Phase II, Randomized, Double-blind, Trial Comparing Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05289830
• Other study ID #: CASE6220
• Status: Terminated
• Phase: Phase 2
• Start date: August 5, 2022
• Est. completion date: August 27, 2023

Study information

• Verified date: June 2024
• Source: Case Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Use of antidepressants for participants with localized pancreatic and periampullary cancer receiving neoadjuvant therapy.

Description:

Anti-depressants have been shown to be beneficial in cancer participants. They reduce depressive symptoms and improve quality of life. Randomized trials have shown that antidepressants can reduce the development of depression in non-depressed participants with breast, melanoma, and head and neck cancers. It has been shown that treating depression can impact survival in cancer participants. Additionally, depressed pancreatic cancer participants have worse survival. Therefore, anti-depressants may also have implications for cancer treatment.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: August 27, 2023
• Est. primary completion date: August 27, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Subjects must have histologically or cytologically confirmed localized or locally advanced pancreatic ductal adenocarcinoma or other periampullary adenocarcinoma (bile duct, duodenal, ampullary)

2. Subjects must not currently be on an antidepressant, anti-anxiety, anti-bipolar, or anti-psychotic medicine

3. Aged 18-80 years.

4. ECOG PS (Eastern Cooperative Oncology Group Performance Status) score of 0-2

5. Planned to have at least 12 weeks of neoadjuvant chemotherapy as standard of care cancer treatment

6. No diagnosis of bipolar disease

7. Willing to comply with all study procedures and be available for the duration of the study

8. Subjects must be mentally competent and must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Patients under the age of 18 or over 80

2. Metastatic pancreatic or other periampullary cancer

3. Resection of pancreatic cancer within the past year prior to study enrollment or planned surgery within the next 12 weeks.

4. Currently on an antidepressant, anti-anxiety, anti-bipolar or anti-psychotic medicine. Patients who have taken MAOIs (Monoamine Oxidase Inhibitors) within the past 6 months are excluded.

5. Patients with a history of seizure disorder

6. Patients with a recent medical history of myocardial infarction or unstable heart disease

7. Patients with a history of QTc prolongation or torsade de points, a baseline QTc

1. interval of > 500ms, a history of drug-induced QTc prolongation or congenital long QT

2. syndrome

8. Patients with Child-Pugh score of B or C

9. Patients with moderate to severe renal disease with a GFR (glomerular filtration rate) < 45.

10. Patients who cannot ingest oral medication

11. Patients with any history of mania

12. Known allergy to escitalopram

13. Pregnancy or lactation

Related Conditions & MeSH terms

• Pancreatic Ductal Adenocarcinoma
• Periampullary Cancer

Intervention

Drug:
• Escitalopram
Participants will receive Escitalopram 2 weeks: 10 mg/day (1 capsule) 8 weeks: 20 mg/day (2 capsules) 2 weeks: 10 mg/day (1 capsule)

Other:
• Placebo
Participants will receive placebo supplements 2 weeks: 1 capsule 8 weeks: 2 capsules 2 weeks: 1 capsule

Locations

Country	Name	City	State
United States	University Hospitals Cleveland Medical Center	Cleveland	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Case Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the rate of depression	The rate of depression will be measured using the Quick Inventory of Depressive Symptoms (QIDS) survey. This survey has 16 questions that are specific to the symptomatology of depression. Answers are given in the form of a four-point Likert scale ranging from 0-3, with zero relating to a standard sense of well-being and three correlating to the greatest feelings of depression. Depression is reflected by a score = 11 (moderate depression or worse).	12 weeks from the start of treatment
Secondary	Quality of Life using FACT-Hep (The Functional Assesment of Cancer Therapy-Hepatobiliary) survey	The FACT-Hep has 27 general questions and 18 questions that are specific to hepatopancreatobiliary cancer, for a total of 45 questions. The general questions span four domains: physical, social/family, emotional, and functional well-being 21. It requires less than 10 minutes to complete and targets the 6th-grade reading level. Answers are given in the form of a five-point Likert scale as follows: 0 (Not at all), 1 (A little bit), 2 (Somewhat), 3 (Quite a bit), and 4 (Very much). Points are re-calibrated and compiled, such that high scores indicate a higher quality of life	Up to 3 years from the treatment date